Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 6 | 2022 | 1103 | 1.330 |
Why?
|
| Liver Neoplasms | 4 | 2021 | 190 | 1.100 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2021 | 145 | 0.960 |
Why?
|
| Adenocarcinoma | 2 | 2022 | 251 | 0.900 |
Why?
|
| Pancreatic Neoplasms | 2 | 2022 | 111 | 0.880 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2020 | 25 | 0.850 |
Why?
|
| Radiology | 1 | 2022 | 10 | 0.850 |
Why?
|
| Medical Staff, Hospital | 1 | 2020 | 13 | 0.750 |
Why?
|
| Internal Medicine | 1 | 2020 | 24 | 0.750 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 17 | 0.730 |
Why?
|
| Internship and Residency | 1 | 2020 | 125 | 0.670 |
Why?
|
| Cooperative Behavior | 2 | 2020 | 219 | 0.660 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 195 | 0.660 |
Why?
|
| Telemedicine | 1 | 2021 | 182 | 0.600 |
Why?
|
| Universities | 1 | 2020 | 442 | 0.560 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 864 | 0.460 |
Why?
|
| Mediastinitis | 1 | 2012 | 3 | 0.430 |
Why?
|
| Mediastinal Neoplasms | 1 | 2012 | 6 | 0.430 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 11 | 0.430 |
Why?
|
| Prognosis | 4 | 2021 | 739 | 0.420 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 1502 | 0.390 |
Why?
|
| Humans | 20 | 2024 | 37093 | 0.390 |
Why?
|
| Colorectal Neoplasms | 2 | 2024 | 441 | 0.380 |
Why?
|
| Perception | 2 | 2021 | 195 | 0.340 |
Why?
|
| Health Status Disparities | 2 | 2022 | 642 | 0.260 |
Why?
|
| Hawaii | 2 | 2022 | 1929 | 0.250 |
Why?
|
| Rectal Neoplasms | 1 | 2024 | 12 | 0.230 |
Why?
|
| Aged | 5 | 2021 | 6741 | 0.230 |
Why?
|
| United States | 4 | 2023 | 4223 | 0.230 |
Why?
|
| Thrombophilia | 1 | 2002 | 4 | 0.220 |
Why?
|
| Prospective Studies | 3 | 2024 | 1378 | 0.220 |
Why?
|
| Hypercalcemia | 1 | 2002 | 13 | 0.220 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 2721 | 0.220 |
Why?
|
| Middle Aged | 6 | 2024 | 10129 | 0.220 |
Why?
|
| Confidentiality | 1 | 2022 | 26 | 0.210 |
Why?
|
| Retrospective Studies | 4 | 2023 | 2026 | 0.200 |
Why?
|
| Electronic Health Records | 1 | 2022 | 66 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 12 | 0.190 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 31 | 0.190 |
Why?
|
| Cohort Studies | 2 | 2023 | 1492 | 0.180 |
Why?
|
| Biopsy | 1 | 2020 | 164 | 0.180 |
Why?
|
| Quality of Health Care | 1 | 2021 | 138 | 0.180 |
Why?
|
| Survival Rate | 1 | 2020 | 311 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 182 | 0.170 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 441 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 268 | 0.170 |
Why?
|
| Male | 7 | 2024 | 20025 | 0.170 |
Why?
|
| Choline | 1 | 2019 | 59 | 0.160 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 2379 | 0.160 |
Why?
|
| Incidence | 1 | 2021 | 922 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 217 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 494 | 0.150 |
Why?
|
| Female | 8 | 2024 | 20969 | 0.150 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2016 | 9 | 0.140 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2016 | 11 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 34 | 0.130 |
Why?
|
| Embryo, Mammalian | 1 | 2016 | 153 | 0.130 |
Why?
|
| Hospitals, Community | 1 | 2015 | 12 | 0.130 |
Why?
|
| Organizational Culture | 1 | 2015 | 14 | 0.130 |
Why?
|
| Adult | 4 | 2021 | 11712 | 0.120 |
Why?
|
| Fibroblasts | 1 | 2016 | 272 | 0.120 |
Why?
|
| Cell Nucleus | 1 | 2016 | 366 | 0.120 |
Why?
|
| Mediastinum | 1 | 2012 | 5 | 0.110 |
Why?
|
| Necrosis | 1 | 2012 | 49 | 0.110 |
Why?
|
| Cell Movement | 1 | 2016 | 571 | 0.100 |
Why?
|
| Granulosa Cells | 1 | 2012 | 42 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 214 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2015 | 400 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2008 | 12 | 0.080 |
Why?
|
| ras Proteins | 1 | 2008 | 51 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2008 | 48 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 275 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 147 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 194 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2008 | 239 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 626 | 0.070 |
Why?
|
| Gene Expression | 1 | 2008 | 674 | 0.060 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2005 | 39 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2005 | 40 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 126 | 0.060 |
Why?
|
| Thromboembolism | 1 | 2002 | 13 | 0.050 |
Why?
|
| Radiography | 1 | 2002 | 72 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2021 | 10 | 0.050 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 4 | 0.050 |
Why?
|
| Propensity Score | 1 | 2021 | 38 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 37 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 143 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 885 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2021 | 156 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 128 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 219 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2021 | 133 | 0.040 |
Why?
|
| Quality of Life | 1 | 2024 | 481 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 325 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 108 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 76 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 131 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 189 | 0.030 |
Why?
|
| Tyrosine | 1 | 2016 | 118 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2016 | 103 | 0.030 |
Why?
|
| Wound Healing | 1 | 2016 | 70 | 0.030 |
Why?
|
| Apoptosis | 2 | 2016 | 1398 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 38 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 251 | 0.030 |
Why?
|
| Leadership | 1 | 2015 | 76 | 0.030 |
Why?
|
| Capacity Building | 1 | 2015 | 87 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 859 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 928 | 0.030 |
Why?
|
| Mice | 2 | 2016 | 5913 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2016 | 1518 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1198 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2009 | 26 | 0.020 |
Why?
|
| Lymphoma, T-Cell | 1 | 2009 | 28 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2009 | 80 | 0.020 |
Why?
|
| Heterozygote | 1 | 2009 | 93 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2009 | 81 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2009 | 326 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 1908 | 0.020 |
Why?
|
| Animals | 2 | 2016 | 15081 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 628 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2005 | 57 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2005 | 55 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2005 | 66 | 0.020 |
Why?
|
| Pregnancy | 1 | 2005 | 1549 | 0.010 |
Why?
|
| Adolescent | 1 | 2005 | 5363 | 0.010 |
Why?
|